<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03150966</url>
  </required_header>
  <id_info>
    <org_study_id>TabrizUMS-Nerve-002</org_study_id>
    <nct_id>NCT03150966</nct_id>
  </id_info>
  <brief_title>The Immunomodulatory Effects of Oral Nanocurcumin in Multiple Sclerosis Patients</brief_title>
  <official_title>The Effects of Oral Nanocurcumin on Expression Levels of microRNAs and Treg Cells and Th17 Cells Development Factors in Multiple Sclerosis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tabriz University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tabriz University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multiple sclerosis is the most common autoimmune disease of the central nervous system, most
      ranging in age from 40-20 years of age is associated with neurons inflammation and
      demyelination. Increasing aggressive activities of Th17 and Th1 cells that their function is
      to secrete proinflammatory cytokines and decreasing the number and activity of regulatory T
      cells, which normally leads to controlling inflammation, are seen in these patients.Curcumin
      is a polyphenol. Curcumin binding with a range of protein and the have ability to inhibit the
      activity of various kinases. Curcumin has a combination of activities such as antioxidant,
      anti-proliferation, anti-invasive, and can used in the treatment of Alzheimer's, Parkinson's,
      Multiple sclerosis, Cardiovascular disease, Bacterial diseases and Arthritis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a randomized double blind clinical trial conducted on two groups. The two
      groups of patients with multiple sclerosis is taking the drug and taking the placebo.
      Patients divided into two groups during the treatment period of 6 months will be received
      either oral nanocurcumin of 80 mg / day and placebo. After sampling both groups and
      separating plasma, peripheral blood mononuclear cells (PBMC) isolated by using Ficoll. PBMC
      is used to measure the expression levels of miRNA-106b, miRNA-25 and miRNA-326. In this
      regard, specific kits extracted miRNA from cells is used. Then the version of miRNA using
      Quantitative Real time polymerase chain reaction(qPCR). . Then the frequency of Treg and Th17
      cells in peripheral blood of patients will be examined by Flowcytometry and compared to the
      control group. The expression of key transcription factor (Foxp3) and specific cytokines
      (TGF-β) related to the Treg cells and key transcription factor (RORγt) and specific
      cytokines, interleukin-17(IL-17), related to the Th17 are measured by Quantitative Real time
      PCR. Elisa methos is used to assess the amount of the cytokine TGF-β and IL-17 in cultured
      cells.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 8, 2016</start_date>
  <completion_date type="Anticipated">September 7, 2018</completion_date>
  <primary_completion_date type="Anticipated">August 10, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum microRNAs</measure>
    <time_frame>6 months</time_frame>
    <description>Evaluate the diagnostic value of microRNAs in quantitative polymerase chain reaction (qPCR), in MS patients as compared with health</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treg cells frequency</measure>
    <time_frame>6 month</time_frame>
    <description>Flowcytometry (Treg cells produce anti-inflammatory cytokines)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Th17 cells frequency</measure>
    <time_frame>6 month</time_frame>
    <description>Flowcytometry (Th17 cells produce inflammatory cytokine and increase inflammation)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory factors expression in PBMC cells</measure>
    <time_frame>6 month</time_frame>
    <description>qPCR method</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory factors expression in PBMC cells</measure>
    <time_frame>6 month</time_frame>
    <description>Elisa method</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Patients who received nanocurcumin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients who received placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nanocurcumin</intervention_name>
    <description>Patients will take 80 mg nanocurcumin in the form of capsules daily during the 6 month study period</description>
    <arm_group_label>Patients who received nanocurcumin</arm_group_label>
    <other_name>Patients who received nanocurcumin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Patients will take placebo in the form of capsules daily during 6 months study period</description>
    <arm_group_label>Patients who received placebo</arm_group_label>
    <other_name>Patients who received placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Willingness to cooperate

          -  Aged 28 to 51 years

          -  The diagnosis of Multiple sclerosis by Neurologist

          -  Patients in Relapsing Remitting (RRMS)

          -  Patients with Expanded Disability Status Scale (EDSS) &lt;5/5.

        Exclusion Criteria:

          -  Use of nutritional supplements and antioxidant and immunosuppressive drugs
             alpha-lipoic acid a month before the study.

          -  Pregnancy and lactation

          -  History of diabetes and other chronic diseases

          -  History of other autoimmune diseases

          -  Occurrence of relapses during the study period

          -  Acceptance rate of less than 70% of supplements

          -  Unwillingness to continue to cooperate
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mehdi Yousefi, Ph.D</last_name>
    <role>Study Director</role>
    <affiliation>Tabriz University of Medical Scienses</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hormoz Ayromlou, Neurologist</last_name>
    <role>Study Chair</role>
    <affiliation>Tabriz University of Medical Scienses</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mehdi Yousefi, Ph.D</last_name>
    <phone>0912 670 3953</phone>
    <email>Yousefime@tbzmed.ac.ir</email>
  </overall_contact>
  <location>
    <facility>
      <name>immunology research center, Tabriz, Iran</name>
      <address>
        <city>Tabriz</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sanam , Dolati</last_name>
      <phone>984133349525</phone>
      <email>dolatis@tbzmed.ac.ir</email>
    </contact>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <reference>
    <citation>Hoang PD, Cameron MH, Gandevia SC, Lord SR. Neuropsychological, balance, and mobility risk factors for falls in people with multiple sclerosis: a prospective cohort study. Arch Phys Med Rehabil. 2014 Mar;95(3):480-6. doi: 10.1016/j.apmr.2013.09.017. Epub 2013 Oct 3.</citation>
    <PMID>24096187</PMID>
  </reference>
  <reference>
    <citation>Schneider A, Long SA, Cerosaletti K, Ni CT, Samuels P, Kita M, Buckner JH. In active relapsing-remitting multiple sclerosis, effector T cell resistance to adaptive T(regs) involves IL-6-mediated signaling. Sci Transl Med. 2013 Jan 30;5(170):170ra15. doi: 10.1126/scitranslmed.3004970.</citation>
    <PMID>23363979</PMID>
  </reference>
  <reference>
    <citation>Schwarz A, Schumacher M, Pfaff D, Schumacher K, Jarius S, Balint B, Wiendl H, Haas J, Wildemann B. Fine-tuning of regulatory T cell function: the role of calcium signals and naive regulatory T cells for regulatory T cell deficiency in multiple sclerosis. J Immunol. 2013 May 15;190(10):4965-70. doi: 10.4049/jimmunol.1203224. Epub 2013 Apr 10.</citation>
    <PMID>23576680</PMID>
  </reference>
  <reference>
    <citation>Jadidi-Niaragh F, Mirshafiey A. Th17 cell, the new player of neuroinflammatory process in multiple sclerosis. Scand J Immunol. 2011 Jul;74(1):1-13. doi: 10.1111/j.1365-3083.2011.02536.x. Review.</citation>
    <PMID>21338381</PMID>
  </reference>
  <reference>
    <citation>Rao TS, Basu N, Siddiqui HH. Anti-inflammatory activity of curcumin analogues. Indian J Med Res. 1982 Apr;75:574-8.</citation>
    <PMID>7118227</PMID>
  </reference>
  <reference>
    <citation>Lescher J, Paap F, Schultz V, Redenbach L, Scheidt U, Rosewich H, Nessler S, Fuchs E, Gärtner J, Brück W, Junker A. MicroRNA regulation in experimental autoimmune encephalomyelitis in mice and marmosets resembles regulation in human multiple sclerosis lesions. J Neuroimmunol. 2012 May 15;246(1-2):27-33. doi: 10.1016/j.jneuroim.2012.02.012. Epub 2012 Mar 22.</citation>
    <PMID>22445295</PMID>
  </reference>
  <reference>
    <citation>Martinelli-Boneschi F, Fenoglio C, Brambilla P, Sorosina M, Giacalone G, Esposito F, Serpente M, Cantoni C, Ridolfi E, Rodegher M, Moiola L, Colombo B, De Riz M, Martinelli V, Scarpini E, Comi G, Galimberti D. MicroRNA and mRNA expression profile screening in multiple sclerosis patients to unravel novel pathogenic steps and identify potential biomarkers. Neurosci Lett. 2012 Feb 2;508(1):4-8. doi: 10.1016/j.neulet.2011.11.006. Epub 2011 Nov 7.</citation>
    <PMID>22108567</PMID>
  </reference>
  <reference>
    <citation>Du C, Liu C, Kang J, Zhao G, Ye Z, Huang S, Li Z, Wu Z, Pei G. MicroRNA miR-326 regulates TH-17 differentiation and is associated with the pathogenesis of multiple sclerosis. Nat Immunol. 2009 Dec;10(12):1252-9. doi: 10.1038/ni.1798. Epub 2009 Oct 18. Erratum in: Nat Immunol. 2010 Jun;11(6):543.</citation>
    <PMID>19838199</PMID>
  </reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 6, 2017</study_first_submitted>
  <study_first_submitted_qc>May 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 12, 2017</study_first_posted>
  <last_update_submitted>January 28, 2018</last_update_submitted>
  <last_update_submitted_qc>January 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple sclerosis</keyword>
  <keyword>Nanocurcumin</keyword>
  <keyword>MicroRNAs</keyword>
  <keyword>Th17 cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

